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Background: When the nature and direction of research results affect their chances of publication, a distortion of
the evidence base – termed publication bias – results. Despite considerable recent efforts to implement measures
to reduce the non-publication of trials, publication bias is still a major problem in medical research. The objective
of our study was to identify barriers to and facilitators of interventions to prevent or reduce publication bias.
Methods: We systematically reviewed the scholarly literature and extracted data from articles. Further, we
performed semi-structured interviews with stakeholders. We performed an inductive thematic analysis to identify
barriers to and facilitators of interventions to counter publication bias.
Results: The systematic review identified 39 articles. Thirty-four of 89 invited interview partners agreed to be
interviewed. We clustered interventions into four categories: prospective trial registration, incentives for reporting in
peer-reviewed journals or research reports, public availability of individual patient-level data, and peer-review/editorial
processes. Barriers we identified included economic and personal interests, lack of financial resources for a global
comprehensive trial registry, and different legal systems. Facilitators identified included: raising awareness of the effects
of publication bias, providing incentives to make data publically available, and implementing laws to enforce prospective
registration and reporting of clinical trial results.
Conclusions: Publication bias is a complex problem that reflects the complex system in which it occurs. The
cooperation amongst stakeholders to increase public awareness of the problem, better tailoring of incentives to
publish, and ultimately legislative regulations have the greatest potential for reducing publication bias.
Keywords: Publication bias, Randomized controlled trials as topic, Trial registration, Access to information, Peer review,
Medical errors/prevention & controlBackground
The non-publication of clinical trial results may lead to
false conclusions about the balance of benefits and harms
of medical interventions and, in turn, harm patients and
waste resources [1]. Publication bias occurs when the pub-
lication of research depends on the nature and direction
of the results – meaning that a study’s positive, negative,
or null result can alter its chances of publication [2,3]. As* Correspondence: christina.kien@donau-uni.ac.at
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unless otherwise stated.awareness has increased about the detrimental effects of
publication bias, the research community and the public
have tried to implement preventive measures such as trial
registries, changes in the peer review process, providing
access to trial data, and others to reduce the non-
publication of clinical trials [3]. According to a systematic
review, however, no evidence currently exists that any of
these interventions are successful in dealing with the
problem [4]. Furthermore, a recent study reported that of
585 registered trials in ClinicalTrials.gov which had been
completed prior to January 2009 133 (23%) provided no
results either in published form or in ClinicalTrials.gov
[5]. This means that an estimated number of 254,000is is an Open Access article distributed under the terms of the Creative
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for studies that never became public knowledge [5]. A sys-
tematic review on the extent of publication bias showed
that the total number of studies not published in each
investigated subgroup (e.g. study protocols approved by
ethics committees or funding granted by research funders)
varies widely from 7% to 79%. Furthermore, 31% to 62% of
studies had at least one primary outcome that was changed
between study registration and publication of results [6,7].
Why measures against publication bias fail remains
unclear. Several stakeholder groups with partially com-
peting interest are involved in the process of funding,
conducting, and publishing research (e.g. researchers,
publishers, sponsors, regulatory agencies). These groups
of stakeholders have different motivations and interests
to publish or not publish research. Information about
barriers and facilitators for measures intended to reduce
the non-publication of trials from the perspective of
these stakeholders would be valuable for designing and
tailoring future interventions.
The objective of our project was to use qualitative
techniques to determine factors that can act as barriers
or serve as facilitators in the implementation of inter-
ventions to prevent or reduce publication bias resulting
from non-publication of clinical trials. We focused on
the non-publication of entire clinical trials which needs
to be distinguished from selective outcome reporting
which occurs if only a selection, on the basis of the
results, of a subset of analyses is to be reported [8].
Methods
To determine factors that can act as barriers to or serve
as facilitators of interventions to prevent or reduce pub-
lication bias, we employed two qualitative approaches.
First, we qualitatively analyzed scholarly articles; second,
we conducted interviews with stakeholders. We chose
this approach to gain a broad overview of opinions of
stakeholders, including those that might be underrepre-
sented in journal articles (e.g. funders, ethics committees).
In addition, we tried to identify and include ideas and
trends which have emerged after the literature search for
this review. The study was registered with the Austrian
Data Protection Authority (number: 4008646) and per-
formed in accordance with data storage and confidential-
ity regulations. We didn’t seek ethical approval at a
research ethics committee as the study did not involve
medical research. The methodology of the interviews
adheres to the RATS guidelines for qualitative research
[9]. In the following sections we describe the methods of
both approaches in more detail.
Review of scholarly articles
The basis of the analysis of scholarly articles was a sys-
tematic review. We searched MEDLINE (via PubMed),the Cochrane Library, EMBASE, CINAHL, PsycINFO,
AMED, and Web of Science up to May 2012. We used
Medical Subject Headings (MeSH) and free text key words
for publication bias and other related biases, as well as for
interventions used to reduce the non-publication of trials
based on Song et al. [3]. We searched for publication and
all related biases (because this search strategy was also
used for a systematic review on the effectiveness of inter-
ventions with a broader scope [4]), so that we could identify
relevant articles on well-known as well as new interventions
to prevent publication bias (Additional file 1). We didn’t
consider interventions such as disclosure of conflict of
interest or large confirmatory scale trials because these are
more relevant for detecting or reducing other forms of
biases such as selective outcome reporting bias. In addition
to electronic searches, we manually searched reference lists
of pertinent reviews and articles.
Two trained research team members independently
reviewed all titles and abstracts identified through
searches. We retrieved and reviewed the full text of all
titles included during the abstract review phase. If both
reviewers agreed that an article did not meet the eligibility
criteria, the study was excluded. If the reviewers disagreed,
conflicts were resolved by discussion and consensus or by
consulting a third member of the review team. We tracked
all results of the literature review in an EndNote® X6 biblio-
graphic database (Thomson Reuters, New York, NY) [10].
One researcher extracted relevant text passages (i.e.,
type of article, intervention, the mentioned barrier or
facilitator and context information), a second checked
correctness. We included different types of scholarly
articles in order to identify expert opinions and common
themes about facilitators and barriers: any empirical
research studies, such as expert interviews or surveys
that examined barriers and facilitators in the implementa-
tion of a measure to reduce publication bias, narrative
literature reviews, editorials, commentaries, and letters to
the editor. We did not perform a risk of bias assessment
because our aim was to give an overview of possible
barriers and facilitators of the implementation of interven-
tions to counter publication bias, not their effectiveness.
For the analysis of the text passages from the included
articles we performed an inductive thematic analysis as de-
scribed by Braun & Clarke [11]. A thematic analysis is a
qualitative method to identify, analyse, and report themes
by searching across a data set – in our case a range of texts.
The first step in the analysis was to assign initial codes to
the text. Similar codes were then combined into themes.
Finally, themes were clustered into higher-ranking themes
(i.e. main categories subsuming descriptive themes). The
themes were identified inductively from the data and were
not predetermined before we started the analysis. We used
the software MAXQDA Version 10 [12] to support the
coding process.
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We conducted semi-structured interviews [13] with repre-
sentatives of relevant stakeholder groups. We defined rele-
vant stakeholders as any group or individual that can
affect or is affected by the publication of a clinical trial,
such as ethics committees, patient organisations, the
pharmaceutical industry, political decision makers, journal
editors or associations, regulatory agencies and supporting
organisations (e.g. trial registries), research funding bodies
and research institutions and associations. We determined
relevant stakeholder groups by developing a stakeholder
map [14]. In general, organisations were the unit of
research because they are thought to have a multiplying
effect in either gathering the perspectives of or in broad-
ening ideas to member institutions or individuals. The
focus was on organisations on the European level (regard-
ing ethics committees, funding or research organisations)
and extended to organisations acting worldwide (e.g. trial
registries, professional organizations) to include inter-
national influences. As interview partners we invited
persons involved in the implementation of new policies or
representatives of relevant European stakeholder groups.
To minimise selection bias, two researchers discussed the
ongoing invitation process. We identified potential inter-
view partners through literature included in the thematic
analysis of articles, extensive internet searches and known
experts of the field. Overall, we used purposive sampling
(i.e. selecting the interviewees who would be most likely
to contribute relevant and in-depth data) [15].
Two researchers developed an interview guide which
focused on questions about reasons for publication bias
and barriers and facilitators regarding interventions to
counter publication bias in general, as well as in relation
to the specific organisation. Four experienced qualitative
researchers led interviews and adapted the interview
guide (Additional file 2) during the process as needed to
enable a fluent interview (semi-structured interview) [16].
We gathered data mainly by telephone or via Skype™
(Version 6.9.0.106) without video and we also conducted
face-to-face interviews. In two cases we accepted
responses to the questions in writing because of schedul-
ing difficulties.
We asked for participant permission to record and
transcribe interviews while maintaining anonymity. All
interviewees provided informed consent. Interviews
lasted between 20 to 50 minutes. We applied the same
thematic analysis approach as described above in the
section on scholarly articles [11]. Two coders assigned ini-
tial codes to the text. Similar codes were then combined
into themes drawing on themes from the thematic analysis
of the articles as a starting point. As new codes were iden-
tified in the analysis of the interviews, we generated new
themes accordingly. To ensure that ambiguity in the cod-
ing and analysis process were reduced, quality assurancemeasures were taken: After one coder finished assigning
codes to the first interview, the results were discussed and
changed if necessary. This process was repeated with the
second coder’s first interview. A discussion process be-
tween two coders was set up to foster the understanding
of the data and to solve ambiguities in establishing themes
[17,18].
Results
Before presenting the combined results of the scholarly
literature review and the interviews, we describe the
identified literature and the sample of interviewees.
Of 2,635 records screened, we included 39 articles for
the thematic analysis of scholarly articles (Figure 1). We
found one empirical research study (web-based survey) on
researcher opinions on registering trial details [19] and
two empirical research studies on the peer review process
[20,21]. We also included six research studies that men-
tioned barriers/facilitators of peer review, and prospective
trial registration in the discussion part of the articles
[22-27]. We identified one article discussing an explana-
tory framework of factors influencing peer review [28].
We found six narrative literature reviews [29-34], eleven
commentaries [35-45], seven editorials [46-52], three let-
ters to the editor [53-55], and two articles that described
specific trial registries [56,57]. Some articles mentioned
barriers and/or facilitators for more than one intervention
to counter publication bias (Additional file 3).
In addition, we invited 89 stakeholders, of which 55
either did not reply after a reminder or refused to be
interviewed (reasons: no time, no expertise on this topic,
organisation’s communication policy, refusing to share in-
formation on this research topic). Thirty-four stakeholders
(response rate: 38%) from nine different stakeholder
groups agreed to be personally interviewed in the time
period between November 2012 and May 2013 (Table 1).
Thirty interviewees represented European or European-
based organisations, four interviewees represented inter-
national organisations. The response rate was similar to
other studies in this field (ranging from 22% [19] to 48%
[58]). We achieved saturation as we observed the recur-
rence of themes between interviewees (i.e. no new items
appeared in the interviews). Further, we completed inter-
views with associations and networks on the European
level for each stakeholder group. Because we were unable
to interview political decision makers, regulatory agencies
and the pharmaceutical industry, we consulted three
policy documents relevant to these groups [59-61]. We
analysed 37 documents in addition to the 39 scholarly
articles.
In the following section we provide a synthesis of results
from the review of articles and stakeholder interviews. We
arrived at four interventions to counter publication bias
based on Song et al. [3] and categorized the information
Figure 1 PRISMA: disposition of the articles.
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interventions: prospective trial registration, incentives for
reporting results in peer-reviewed journals or reports,
policies regarding public availability of individual patient-
level data and the peer-review and editorial process.
We mark barriers and facilitators in italic font. Verbatim
quotes from interviewees are presented with quotation
marks. Table 2 provides an overview of identified barriers to
and facilitators of interventions to counter publication bias.
Prospective trial registration
Prospective registration of all clinical trials in a searchable
and comprehensive registry can ensure that basic informa-
tion about all trials is accessible to the public [36]. This
can help researchers identify the proportion of unpub-






Publishing (journal editors, associations)
Regulatory agencies and supporting organizations (e.g. trial registries)
Research funding bodies
Research institutions and associations
Other groups: networks, associations
Overalltrials and mandatory reporting of results within one year
of trial termination [62]. The European Medicines Agency
(EMA) requires researchers to include details of clinical
trials concerning medicinal products for human use in the
European clinical trials database (EudraCT, established in
May 2004) within the authorisation process. Since March
2011, limited information on trial methods – but no
results – are publically available through the EU Clinical
Trial Registry (EU CTR) [63]. The law does not require
the inclusion of other interventions such as studies
concerning medicinal devices or other non-drug-trials. In-
formation contained in registries is often incomplete [6,7].
Barriers
Authors discussed economic and personal interests as major











Table 2 Identified barriers and facilitators for possible interventions to counter publication bias
Barriers Facilitators
Prospective trial registration
• Competing economic or personal interests of different stakeholders • Trial registration as a prerequisite for crucial decisions within research
(e.g. approval from ethics committees, publication by journal editors,
condition of funding)
• Lack of mechanism to enforce trial registration • One comprehensive trial registry
• Lack of awareness of the problem • One unique registration number
• Imperfect data quality (e.g. incomplete data entries) • Provision of resources to maintain trial registries
• Lack of sufficient resources to enable registries to improve data quality • Raising awareness
• Many trial registries with different purposes exist • Educating stakeholders
• Different legal systems in different countries • Support of all stakeholders
Incentives for reporting in peer-reviewed journals or research reports
• Lack of prestige for publishing negative findings • Guidelines for Good Clinical Practice
• Perceived lack of possibilities to publish • Right to publication
• Monitoring of publication status by ethics committees via providing
a route to maintain a track record
• Retaining a certain percentage of the research grant until results have
been published by funders
• Law requiring publication of results
Public availability of individual patient level data (IPD)
• Competing financial or career related interests • Incentives for making IPD publically available (reputation and credibility,
proliferation and efficiency of health care research, development of a
new research evaluation system)• Safeguarding the privacy of patients
• Reporting requirements • Fostering cooperation and exchange between researchers
• Missing quality checks • Law requiring the (restricted) public availability of IPD
• Complex technological requirements • Monitoring of complying and mechanisms of enforcement
Peer-review process and editorial processes
• Influenced reviewers and editors • Enforcing objectivity
• Cultural norms and behaviours • Disclose of conflict of interest
• Inconsistencies in the process • Use of professional peer reviewers
• Lack of consistent qualifications • Training for peer review and editors
• Peer review only introduction and methods part of a manuscript
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could occur with the registration of trials [19,24,33,52,57].
They believe that publication of information on new
developments could threaten confidentiality and lead to
competitive disadvantages [31,33,35,51]. Academic
researchers also have competing interests, such as the
right for exclusivity on research ideas [19,33,51].
Although the US and EU have adopted laws requiring
trial registration as well as the reporting of results, the
US and EU have not implemented monitoring or mecha-
nisms of enforcement [29,31,36,43,50]. A lack of awareness
of the problem and the consequences of publication
bias was identified as a barrier [31]. In identifying the
shortcomings of trial registries, several articles men-
tioned the imperfect quality of data [26,27,46], as wellas the lack of sufficient resources to enable registries to
check and improve the quality of included data
[29,31,52]. Furthermore, although many trial registries
exist worldwide, they vary greatly in their stages of
development, coverage, and goals. In addition, different
groups may be in charge [31,50,52,56]. The World
Health Organization International Clinical Trials Regis-
try Platform (WHO ICTRP) has defined specific criteria
for content, validity, etc. and listed trial registries which
meet these criteria [64]. The broad range of registries
makes the effort to locate and capture all trials from
such a wide variety of sources difficult [36,52]. Any
initiative to create a worldwide uniform trial registry
would have to conform to the laws of often vastly
different legal systems [29,50,52].
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Mechanisms to enforce trial registration could increase
the amount of trials registered and improve the quality
of data. One interviewee said: “For registers to be very
comprehensive there is a need for sometimes more than
just guidelines and recommendations” (Interviewee [I]
#9, 61). This opinion was echoed by several other inter-
viewees. As a solution, some authors suggested imposing
monetary penalties, withholding future funding, or issu-
ing public notices of noncompliance [25,30,31,33,51].
One mechanism on the regulatory side could be to tie li-
censing with prospective registration. Only drugs with
studies which have been prospectively registered will be
considered for licenses (e.g. will be considered in the
current Regulation of the European Parliament and of
the Council on clinical trials on medicinal products for
human use, repealing Directive 2001/20/EC [61] and
was considered in the U.S. Test Act [65]).
Both interviewees and authors suggested that trial regis-
tration should be a prerequisite for crucial decisions within
research (e.g. trial approval from ethics committees, deci-
sion from research funding bodies) [22,31,33,41,43,50].
Since 2013, trial registration is required as a prerequisite
for ethical approval in the UK [66,67]. Registration as a
prerequisite for consideration of publication in peer-
reviewed journals was implemented in September 2005 by
the International Committee of Medical Journal Editors
(ICMJE) [68] and resulted in an increase in the number
and proportion of clinical trials being prospectively regis-
tered by 73% between May and October 2005 from 13,153
to 22,714 [69]. Despite this policy, ICMJE-member jour-
nals showed a lack of monitoring and enforcement of this
policy [7] and many journals have not implemented this
policy at all [24,26,29,33,35,46]. An interviewee recom-
mended that journals should “retake their vows, like
people do with marriages sometimes” (I#10, 41).
Overall, having one comprehensive trial registry for all
trials and using a unique registration number would sim-
plify the search for trials [29,31,34,50], and would enable
the differentiation between multiple studies and multi-
center trials [29,31,36,43]. As interviewees added, trans-
parency could be fostered by linking study protocol, trial
registration, and publication of results. Authors recom-
mended worldwide legislation that mandates registry of
trials and international linked registries [29]. One inter-
viewee highlighted an example where surveillance and
control of health problems that do not have international
boundaries were tackled at an international level, namely
the World Health Organisation (WHO) Framework Con-
vention on Tobacco control [70].
Articles call for governments and the pharmaceutical
industry to provide resources to maintain trial registries
[29,33,43]. In order to guarantee independence from the
pharmaceutical industry, an independent fund for trialregistries with blind financial support from different
sources could be established. Appropriate software to
manage such a huge amount of information is described
as a necessary resource [29,52]. Further, better usability
(simplification of the process, improvement of the
explanatory text including requirement for registration)
would foster the uptake and the quality of entries in trial
registries [26,29,31].
To increase the prospective registration of studies, ini-
tiatives should focus on raising awareness, as well as edu-
cating and gaining the support of stakeholders (research
funders, sponsors of trials, governments, journal editors)
[31,33,48]. Representatives of trial registries, funders,
ethics committees, and journal editors pointed out that an
important part of their work is to inform researchers
about the necessity of registering trials and properly
reporting clinical trial results. Another interviewee men-
tioned the need to address the consequences of publica-
tion bias in the curriculum of researchers, stating “I think
that’s a thing where those [of us who] have been involved
in teaching medical students have probably not been as
effective as we should have been. And I think that’s
because the extent of the problem of publication bias is
something that we ourselves have not really fully taken on
board.” (I#15, 36). Later on the interviewee added that he
became only fully aware of the consequences of publica-
tion bias via the “All Trials Registered – All Trials
Reported Campaign” (www.alltrials.net) which was set up
in January 2013 [71].Incentives for reporting in peer-reviewed journals or
research reports
The proportion of published trials also depends on the
motivation of investigators to submit results for publica-
tion to peer-reviewed journals [72]. Half of European
Union health-related funded studies between 1998 and
2006 were not identifiably published [73]. The following
section addresses barriers and facilitators on incentives
and regulation for reporting in peer-reviewed journals or
research reports.Barriers
An important identified barrier in the interviews was a
lack of prestige for publishing negative results. One
interviewee said: “Clearly that’s not as prestigious nor is
it interesting and [researchers] don’t get cited […]. You
do not go to a [grant] body with a negative result.” (I#8,
14). Research shows that positive results are cited more
often than negative results, and the impact factor
calculation of journals depends on citations [74,75].
Currently, the impact factor is used as a decision base
for career advancement for researchers and grant
awards [76].
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publish. Several interviewees argued that in accordance
with “the freedom of the press,” journals should continue
to be able to select what they want to publish. Although
several journals do exist for the sole purpose of publishing
indeterminate or null findings, these must not be so
well-known since several interviewees, in particular, re-
searchers, suggested that such journals should be created.
The interviewees as well as authors argued that public
funding could separate the publication process from finan-
cial constraints and therefore facilitate the existence of
such journals [47].
Facilitators
Authors and interviewees suggested different ways to
foster the reporting of results. Several authors argued
that it is an ethical responsibility to share all results [35].
A similar vein is followed by Guidelines for Good Clinical
Practice, such as The Declaration of Helsinki (DoH) issued
by the World Medical Association [77] and The European
Code of Conduct for Research Integrity [78]. They are
relevant to publication bias as both the DoH [77] and the
European Code of Conduct [78] explicitly mention that
research results have to be published. In general, inter-
viewees considered the Code of Conduct as “theory” and
viewed funding bodies as having the necessary leverage to
ensure that research institutions accept and implement
these guidelines. Interviewees recommended that the
DoH and the Code of Conduct should be an integral part
of PhD-programs and could be promoted further through
talks and international seminars. Overall, interviewees
admitted, that there is no ideal process to disseminate
guidelines due to legal and cultural differences. Inter-
viewees also highlighted the necessity of insisting on a
contractual right to publication of research results when
cooperating with sponsors.
Many authors considered ethics committees to be in
the ideal position to enforce the dissemination of trial
results; they could require reports and send them to a
central, comprehensive, and multidisciplinary registry
which would have to be set up [41,54,55]. If ethics com-
mittees take on this role, it will be important that they re-
ceive appropriate resources [50]. One interviewee
suggested that this could be fostered by providing an auto-
matic route to maintain a track record of transparency. In-
terviewees from European countries other than the UK
explained that research ethics committees must be harmo-
nized nationally and across Europe to enable this role (e.g.
standardized operating procedures, a well-functioning
application system, on-going training of ethics committees
members, and quality assurance measures).
Funding bodies could also ensure that the results of
financed trials are publicly disseminated [47,50]. Several
European funding bodies have policies regarding thepublication of trial results in open access journals [79]
but these policies are not always mandatory or include
no enforcement mechanisms. Interviewees suggested
that only research organisations with publication policies
should receive funding in order to transfer policies and
norms from funding organisations to research organisa-
tions. In a further step, interviewees requested that fund-
ing bodies put sanctions in place for failure to publish,
such as retaining a certain percentage of the research
grant until results have been published. For this to hap-
pen, interviewees mentioned that the following points
need to be taken into consideration: First, sanctions can
be implemented only if they adhere to national laws.
Second, national funding bodies often consist of a broad
range of funders, meaning that proposed sanctions
might be subject to an extensive approval process.
Public availability of individual patient-level data
Although trial registration is important for detecting
publication bias, several authors and interviewees argued
that another great need exists for full availability of
individual patient-level data (IPD) of clinical trials: “We
cannot rely on what people make available in tables, we
already know that. So we also need access to the raw
data, so that there can be an independent assessment of
the same data” (I#1, 22). In November 2012, the EMA
stated that they are committed to the “proactive publica-
tion of data from clinical trials supporting the authorisation
of medicines once the marketing-authorisation process has
ended, which the EMA does not consider commercially
confidential” [80]. The EMA issued a draft policy on access
to clinical trial data [60], and declared that it would not
proactively publish clinical trial data but would “give the
possibility to download, save and print the trial data for
academic and non-commercial research purposes” by
October 2014 [81]. Some interviewees argue that the publi-
cation of summary results is sufficient, especially, as several
barriers remain.
Barriers
University and pharmaceutical industry researchers may
have competing interests when it comes to publishing (or
not publishing) IPD due to career or financial concerns.
Researchers may be reluctant to publish results in a
registry before publication in peer-reviewed journals,
even if the journals would accept such pre-publication
[19]. Interviewees stated that researchers usually want to
publish several articles based on one data set because
randomised controlled trials (RCT) tend to be very
resource and time intensive. Several interviewees men-
tioned concerns over authorship and recognition for
data providers when others conduct subsequent analyses
on data provided in registries. Pharmaceutical companies
are especially concerned about losing their competitive
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[59] were made publically available. Several interviewees
mentioned the need to safeguard the privacy of patients
if IPD were made publically available, especially regard-
ing socially stigmatized or rare diseases. Special concerns
were raised regarding misuse or manipulation which
could occur through linkage of data with other data
carriers [60]. Some interviewees argued that anonymisa-
tion strategies may not be full proof. If the protection of
patient privacy is to remain a primary goal, then the
small risk that individual patients could be identified
must be weighed against the overall public health gains.
Interviewees and authors argued that solutions for
reporting requirements are needed [82,83]. Study details
such as randomisation and allocation concealment
procedures and intervention descriptions should be
provided so that, “data aren’t just publically available but
publically understandable” (I#4, 106). For data submitted
to the EMA, the required standard will be the Clinical
Data Interchange Standards Consortium (www.cdisc.org)
[60]. One interviewee argued that for IPD reporting,
open standards that are publically available and subject
to discussions and change, should be applied to avoid
lengthy reporting standard discussions.
Another barrier interviews and articles identified to the
usage of data repositories was missing quality checks of pub-
lically available data as well as planned secondary analyses
[40]. To store and search for IPD, technological systems are
required that are more complex than those needed for the
storage of pdf-formatted articles. Interviewees mentioned
several examples of such registries, such as the Dataverse
Network™ Project (http://thedata.org) [84].
Facilitators
Interviewees mentioned the following incentives for mak-
ing IPD publically available. In contrast to concerns raised
by pharmaceutical companies regarding competitive
advantage losses, interviewees highlighted gains in reputa-
tion and credibility due to improved transparency. They
mentioned increased efficiency in health care research due
to aspects such as improvements in comparative-
effectiveness analyses and validation of outcome assess-
ments [39,45]. Interviewees reasoned that given recent
cases of scientific misconduct in the academic field, aca-
demia would also benefit. With regards to the role of im-
pact factors in the academic world, one interviewee
explained how research funders imagined a different
evaluation system of conducted research: “When [research
funders] evaluate projects [they should] not just look at
publication lists of the principal investigator, but also at
researcher’s record in storing and managing data, in pub-
lishing open access and not only in high impact journals”
(I#11, 36). Furthermore, one interviewee added, that fos-
tering cooperation and exchange between researcherswould be an important basis for sharing data. Journal
editors also have a stake in credible and transparent
research, and therefore support open access to data [85].
Several interviewees who support public availability of
IPD highlighted the need for a law which requires the
publication of results, and IPD in particular, which is
in line with data protection requirements [45]. Preferably,
an interviewee reasoned, cooperation would occur be-
tween different nations with the goal of passing similar
laws to exert a common effect on industry or individual
researchers and prevent the pharmaceutical companies’
drift to Non-European countries. Again, monitoring of
compliance with a law and different mechanisms of
enforcement were discussed in both the interviews and
the articles (e.g. financial sanctions [45], posting non-
compliance on professional or patient organisations web-
sites, including statements in Cochrane Reviews regarding
the amount of data of clinical trials could not be consid-
ered in the assessment of a certain treatment due to public
unavailability).
Changes in peer review and editorial processes
Journal peer review has been defined as “the assessment
by experts (peers) of material submitted for publication
in scientific and technical periodicals” [86] aiming to
improve the general quality of a study [3].
Barriers
Peer review is a highly subjective process; personal know-
ledge [28], private interests of reviewers such as profes-
sional affinities or rivalries [21,42], a preference towards
interesting topics and favourable results [23], or towards
the confirmation of their own thinking [28,49] can affect
the review (i.e. biased reviewers). Similarly, editors can be
influenced by their personal beliefs and attitudes (i.e.
biased editors) [21,28]. Both authors and interviewees
argued that manuscripts of studies with failed treatments
are less likely to be cited which can influence the impact
factor of the journal and may therefore lead to rejection by
the editors [20,38]. One interviewee added that editors also
tend to reject manuscripts that are industry-funded. Sev-
eral interviewees pointed out that the perceived barrier of
biased reviewers and editors may prevent authors from
pursuing publication. Some admit that while publication of
negative results may be possible, it is less likely in the most
prestigious journals. This results in an imbalance between
the work required to publish and career advancement. An
interviewee gave the following example: “Because journals
want something, which […] will be quoted often, [… and]
will make some kind of impact, […] saying that something
does not work […], may end up, in a [non-English] journal
and not in a good international one” (I#20, 18). Further, an-
other interviewee stated, “I think research does suffer, so,
so we do need to change that perception” (I#6, 73).
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view process as one perceived barrier [21,42]. For instance,
codes of practice among medical journal editors are vol-
untary and do not appear to be common [28]. Consistent
criteria may be lacking for the selection of peer reviewers
[23,40] and manuscripts [21,37]. Although training man-
uals such as from the Committee of Publication Ethics
(COPE) or European Association of Science Editors
(EASE) for editors and peer reviewers are available, they
do not seem to enjoy widespread use [20,42].
Facilitators
The articles discuss several ways to overcome inconsisten-
cies in the peer review process: enforcement of transpar-
ency through publication of abstracts along with an
explanation for rejections [49]; enforcement of objectivity
through incorporation of opinions from a wide range of
experts [49] or implementation of an agreed upon quanti-
tative measurement in the peer review process, familiar to
all manuscript authors [37]; the inclusion of a statement of
conflict of interest for reviewers and editors to identify
personal relationships, academic rivalries, or personal, pol-
itical, or ideological persuasions were proposed [21,49];
usage of fulltime, experienced professional peer reviewers
and editorial boards to facilitate proper implementation
of the peer review process [42] and the introduction of
training for peer reviewers and editors in scientific ap-
praisal of the submitted manuscripts [21,42,49] as well as
the raising of awareness that manuscripts with neutral or
negative results are of interest and value to the scientific
community and study quality, not just positive outcomes,
should be the focus [20,23,32]. Other proposals focused
on the parts of a manuscript which should be subject to
peer review to prevent reviewers from being biased by the
results of the study: only the introduction and methods
sections, everything except the results [53] or the peer
review of the protocol. If it’s determined to be good, the
journal commits to at least sending the manuscript of the
study out for peer-review. This way an editorial commit-
ment is made before the results are known [44].
Discussion
To our knowledge, our study is the first to provide a
comprehensive analysis of barriers and facilitators of the
publication of trial results as discussed in published
literature and gained from interviews with stakeholders.
Our approach enabled us to verify the results gained
from the literature review, to use interviews to put re-
sults of the literature review into perspective and identify
new insights not addressed in the literature. The most
common barriers to trial publication included economic
or personal interests, lack of sufficient funding for a
comprehensive trial registry, differing legal regulations,
and concerns over patient privacy. Important facilitatorswere incentives for the publication of statistically non-
significant results (e.g. research funders adopt perform-
ance metrics including full dissemination of research
and providing data sets), and laws for the enforcement
of prospective registration and reporting of clinical trial
results. A common theme in our analyses is the neces-
sity of an increase in public and researchers’ awareness
of the detrimental effects of publication bias on health
care. A second overarching theme was that publication
bias is a complex problem that demands mutual support
within and across stakeholder groups. Such a manifold
approach has also been recently highlighted [87].
Our study has several limitations. First, because of the
lack of empirical data on barriers and facilitators for the
publication of trials, we had to focus on editorials and
discussions that expressed the personal opinions of
authors active in the academic and regulatory field.
Interviews provided the opportunity to integrate per-
spectives of different stakeholders such as funders, ethics
committees, and industry representatives that are not as
well represented in the scientific literature as researchers
(e.g. role of funding bodies in the implementation of the
Code of Conduct in European research organizations,
needed harmonization of ethics committees within a
country but also across Europe to apply to the role of
monitoring publication status).
Second, our literature search covered only the time
period up to May 2012. Many new articles on publication
bias have been published since then. However, we believe
that we captured more recent trends in interviews, con-
ducted almost one year later (e.g. AllTrials Initiative and
the associated discussion of making IPD publically available,
direct interaction of trial registries with funding bodies).
Third, we conducted interviews with all relevant stake-
holder groups and consulted policy documents when
stakeholders declined to be interviewed. Because each
interviewee was an expert in a specific area, not all ques-
tions relating to publication bias could be posed to every
interviewee. However, recurring themes across interviews
suggest that the number of interviews was sufficient.
Overall, the topic of publication bias has been a hotly
debated subject in recent years. Although we have con-
ducted a thorough literature review and a purposive sam-
pling of interviewees, we may have missed some barriers
and facilitators (e.g. time and personnel costs for making
IPD publically available). Furthermore, two online portals
were started in January 2014 by the pharmaceutical indus-
try to gain access to results of clinical trials to researchers
[88,89], therefore not reflected in the results of our inter-
views or literature review.
Our study focuses on the European situation and the
specific role of certain stakeholders (e.g. research funders,
ethics committees, research organizations). However,
since pharmaceutical companies and academic research
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we also discussed barriers and facilitators on a global level
(e.g. WHO ICTRP, ICMJE, international laws concerning
trial registration) affecting the specific European situation.
Nevertheless, we believe that the extent to which results
can be generalized beyond the European context is
limited, specifically in relation to current barriers and
facilitators in trial registration in developing countries
[90,91]. Although some interventions may also be relevant
for detecting or countering selective outcome reporting bias
(e.g. trial registration), the focus of our study was on non-
publication of clinical trials. Therefore we did not cover any
measures specific to selective outcome reporting bias.
Findings of our study also highlight several general
and contextual issues that policy makers need to address
to facilitate the publication of trial results. One recurring
theme concerned the problems of differing health care
and research systems worldwide (e.g. local ethics commit-
tees, national funding bodies, etc.). Several initiatives are
currently underway to address these challenges and to
build a basis for mutual exchange by creating common
standards and procedures and promoting collaboration
via the exchange of good-practice examples (e.g. fostering
exchange on funding requirements, promotion of guide-
lines on research integrity, research ethics committees,
e.g. EUREC [92]). The WHO ICTRP supports the devel-
opment of common standards and fosters a meta-registry
with a unique identifier number [93]. We recommend
strengthening these networks (e.g. fostering learning via
the publication of good-practice examples) and increasing
financial resources (e.g. for the WHO ICTRP by members,
i.e. individual states; for European based networks such as
EUREC by research programs). A second issue concerns
the lack of mandatory reporting of clinical trial data and
results. The EU Clinical Trial Regulation, which was
implemented in June 2014, but will not come fully into
force until May 2016, could become a milestone with
respect to transparency of clinical trial data and results
[61,94,95]. A third problem repeatedly mentioned in inter-
views and by academic stakeholders concerned the lack of
awareness among researchers with respect to the detri-
mental effects of publication bias. Efforts should be made
to train and educate researchers regarding publication bias
and usage of trial registries. These initiatives should
include highlighting journals such as the Journal of
Pharmaceutical Negative Results, the Journal of Unsolved
Questions (JUNQ), and the Journal of Negative Results in
BioMedicine that publish indeterminate or null findings.
In addition, public pressure is needed to urge lawmakers
to pass legislation that requires trial and result reporting
and includes effective measures of enforcement. Until
legal changes become effective, interviewees suggested
that systematic reviewers who are unable to obtain unpub-
lished data [96] and are confronted with publication biascould use systematic reviews and press releases to draw
public attention to those who do not publish trial results.
Finally, the lack of consequences for not publishing trial
results makes existing measures ineffective. Trial registra-
tion and reporting of results should be prerequisites for
the acceptance of trial results by regulatory agencies. Pub-
lication strategies need to become a mandatory aspect for
ethics committees. In the future, a priori registration, open
access to trial data, and open access publications have to
become prerequisites for receiving grant money funded by
tax payers.Conclusions
Our study used a novel approach in combining a system-
atic review of articles with qualitative interviews to iden-
tify barriers to and facilitators of four interventions to
counter publication bias: prospective trial registration, in-
centives for reporting results in peer-reviewed journals or
reports, policies regarding public availability of IPD and
changes in the peer-review and editorial process. One im-
portant first step to overcome barriers of interventions to
counter publication bias is to increase public and stake-
holder awareness of the effects of publication bias on
health care and patients through education. Furthermore,
the cooperation between stakeholders to implement inter-
ventions to counter publication bias, using new perform-
ance metrics and therefore creating new incentives for
researchers to disseminate their results and data and ul-
timately legislative regulations have the greatest potential
for reducing publication bias.Additional files
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